Advertisement

Huisarts en wetenschap

, Volume 44, Issue 8, pp 399–405 | Cite as

Hormonen na de overgang: goed voor hart- en bloedvaten?

  • MJJ de KleijnEmail author
Beschouwing
  • 36 Downloads

semenvatting

Postmenopauzale vrouwen hebben een verhoogd risico op hart- en vaatziekten vergeleken met premenopauzale vrouwen. Dit artikel vat de resultaten samen van het wetenschappelijk onderzoek naar de effecten van hormoontherapie (oestrogenen en progestagenen) op hart- en vaatziekten bij postmenopauzale vrouwen.

Hormoontherapie beïnvloedt het lipidenprofiel, de vasodilatie van slagaders en de mate van atherosclerose gunstig. Tijdens het gebruik van hormoontherapie neemt de stollingsactiviteit echter toe. In observationeel onderzoek wordt een sterke afname van het risico op hart- en vaatziekten in hormoongebruiksters gevonden. Deze bevindingen worden echter niet bevestigd door de resultaten van de eerste ‘randomized controlled trials’. Het risico op veneuze trombose en borstkanker neemt toe door hormoongebruik. Het zoeken naar alternatieven zoals selectieve oestrogeen receptor modulatoren (SERM&'s) en plantaardige (phyto) oestrogenen is nog in volle gang.

Op dit moment is er in de huisartsenpraktijk geen plaats voor de behandeling van postmenopauzale vrouwen met hormoontherapie ter voorkoming van hart- en vaatziekten.

hart- en vaatziekten hormonale therapie overgang 

Literatuur

  1. Elders P, Van Keimpema JC, Petri H, et al. NHG-Standaard Osteoporose. Huisarts Wet 1999;42:115-128.Google Scholar
  2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.CrossRefGoogle Scholar
  3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.CrossRefGoogle Scholar
  4. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613.CrossRefGoogle Scholar
  5. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.CrossRefGoogle Scholar
  6. Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/ progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030-2037.CrossRefGoogle Scholar
  7. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.CrossRefGoogle Scholar
  8. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97:979-986.CrossRefGoogle Scholar
  9. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.CrossRefGoogle Scholar
  10. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952.CrossRefGoogle Scholar
  11. Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98:1158-1163.CrossRefGoogle Scholar
  12. De Kleijn MJJ. Hormone replacement therapy and endothelial function. Epidemiologic studies on estrogen and cardiovascular disease in post-menopausal women. 2000; 100–111. Thesis. Julius Center for General Practice and Patient Oriented Research, University Medical Center Utrecht.Google Scholar
  13. Van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71:663-670.CrossRefGoogle Scholar
  14. McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clinical Endocrinology 1996;45:435-441.CrossRefGoogle Scholar
  15. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the agerelated decline in endothelium-dependent vasomotor function. Circulation 1998;97: 234–1238.CrossRefGoogle Scholar
  16. Westendorp ICD, De Kleijn MJJ, Bots ML, et al. The effect of hormone replacement therapy on arterial distensibility and compliance in peri-menopausal women: a two year randomised trial. Atherosclerosis 2000;152:149-157.CrossRefGoogle Scholar
  17. Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-1019.CrossRefGoogle Scholar
  18. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.CrossRefGoogle Scholar
  19. Van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Res 2000;83:29-34.Google Scholar
  20. The Writing Group for the Estradiol Clotting Factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75: 476–480.CrossRefGoogle Scholar
  21. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-1075.CrossRefGoogle Scholar
  22. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.CrossRefGoogle Scholar
  23. Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.CrossRefGoogle Scholar
  24. Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995;191:150-164.PubMedGoogle Scholar
  25. Hemminki E, McPherson K. Impact of post-menopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-153.CrossRefGoogle Scholar
  26. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.CrossRefGoogle Scholar
  27. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast-cancer in post-menopausal women. N Engl J Med 1995;332:1589-1593.CrossRefGoogle Scholar
  28. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. Results of the Iowa Women’s Health Study. JAMA 1999;281:2091-2097.CrossRefGoogle Scholar
  29. Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-1332.CrossRefGoogle Scholar
  30. Mijatovic V, Netelenbos C, Van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homo-cystein levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-1089.CrossRefGoogle Scholar
  31. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N.Engl.J.Med 1995; 333:276-282.CrossRefGoogle Scholar
  32. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol.1997;17:3392-3398.CrossRefGoogle Scholar
  33. Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999;354:2112-2115.CrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2001

Authors and Affiliations

  1. 1.

Personalised recommendations